Blog

FSD Pharma Completes Harvest and Microbial Testing of First Lot

TORONTO, August 21, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) is pleased to announce that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”), completed the harvest of its first lot of cannabis and successfully passed microbial testing required by Health Canada under the ACMPR and will be harvesting its second lot this week so as to conduct full analytical testing, thereby positioning FV Pharma to request a Pre-Sales License Inspection from Health Canada. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the ACMPR. Continue Reading

Fsd Pharma and Scicann Therapeutics Launch Clinical Research Program in Israel

CSE: HUGE
OTC: FSDDF
FRA: 0K9

TORONTO, August 16, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9), announced today the launch of a clinical research collaborative program in Israel, via its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann”)

This comprehensive clinical research program will be executed through SciCann’s strategic alliance and collaboration agreement with Mor Research Applications Ltd. (“Mor”) – the technology transfer office and commercial arm of Clalit Healthcare Services, Israel’s largest medical insurer and healthcare provider, which operates a network of 14 full scale hospitals throughout Israel, employs over 9,000 physicians and serves the healthcare needs of over 50% of Israel’s population. Continue Reading

FSD Pharma Announces Listing on Frankfurt Stock Exchange

CSE: HUGE
OTC: FSDDF
FRA: 0K9

TORONTO, August 14, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) announced today that its subordinate voting shares are now listed on the Frankfurt Stock Exchange (“FRA”) and are trading under the “WKN: A2JM6M” and the ticker symbol “0K9.” The Company’s subordinate voting shares continue to be listed on the Canadian Stock Exchange (“CSE”) under the ticker symbol “HUGE” and on the OTC in the US under the ticker symbol “FSDDF.” Continue Reading

FSD Pharma Inc. announced appointment of Dr. Raza Bokhari as new director

TORONTO, August 2, 2018 /CNW/ – FSD Pharma Inc. (“FSD“) (CSE: HUGE) (OTC: FSDDF), is pleased to announce the appointment of Dr. Raza Bokhari to its Board of Directors, effective immediately.

Dr. Bokhari currently serves as the Chairman & CEO of PCL, a global diagnostic provider of addiction screening and opioid prescription medication monitoring, including designer drugs and synthetic cannabinoids. He is also the managing partner of RBx Capital, LP.  Recipient of Philadelphia Business Journal’s “40 under 40” award, physician turned entrepreneur, Dr. Bokhari has over the past several years developed outstanding expertise in aggregating and accelerating life sciences and healthcare services companies. He has a vast knowledge base of developing creative concepts, implementing programs and forming strategic alliances. An effective “change agent”, with several years of experience and expertise in start-up and turn-around businesses, he is adept at turning around financially struggling companies. Dr. Bokhari recognizes the special role of private equity funds, venture capital money, and leveraged debt partners in executing accelerated growth trends in healthcare services and cancer diagnostics and therapeutics. Continue Reading

FSD Pharma Surpasses One Billion Shares Traded and Makes History With Annual CSE Volume Trading Record in Less Than Two Months

TORONTO, June 20, 2018 /PRNewswire/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTC: FSDDF), is pleased to report that it has traded over one Billion Class B subordinate voting shares and has broken the one year consecutive days of trading record on the Canadian Securities Exchange (“CSE”) in less than two months of trading. During the period of May 29, 2018 to July 18, 2018, the Company traded exactly 1,028,297,481 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”). Comparatively, the largest amount traded prior on the CSE in a one year period of consecutive days was 989,295,522. This is the largest total quantity of share volume ever traded by a CSE listed issuer within one year of consecutive days of trading as confirmed by the CSE. Continue Reading

Business Television: HUGE Shares Traded For Cannabis Company

This cannabis company surpassed one billion shares traded on the CSE. FSD Pharma, owns, through its wholly-owned subsidiary FV Pharma Inc., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) which was originally granted on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FSD Pharma’s management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FSD Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development.

FV Pharma is a licensed producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR), having received its cultivation license on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FV Pharma management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FV Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development.

FSD Pharma Quebec Partner Cannara Biotech Closes Over $17.6 Million Equity Financing to Begin Build Out of First Phase of 625,000 Square Foot Indoor Grow

TORONTO, July 24, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) (OTC:FSDDF) is pleased to announce its strategic partner Cannara Biotech Inc. (“Cannara”) closed $17.66 million common share equity financing.

FSD is a significant Cannara shareholder and has applied for a second site license at the Cannara facility. FSD made an investment of $1 million dollars in this round of financing. First Republic Capital Corp. was the sole broker for the offering, the proceeds of which will support the first Phase build-out at Cannara’s Farnham, Quebec facility, as well as fund product development. Continue Reading

FSD Pharma Appoints a Special Committee of the Board for Mergers and Acquisitions and Interim Chief Financial Officer

TORONTO, July 23, 2018 /CNW/ – Thomas Fairfull, President and Chief Executive Officer of FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) (OTC:FSDDF), is pleased to announce the appointment of a Special Committee of the Board of Directors to focus on Merger and Acquisition Opportunities and also the appointment of Donal Carroll as interim Chief Financial Officer. Continue Reading

FSD Pharma Stock Appears to Have Enormous Potential

FSD Pharma Inc.’s (CSE:HUGE) mission is to transform a former Kraft food plant into the largest hydroponic indoor cannabis facility in the world

SmallCapPower | July 20, 2018: FSD Pharma Inc. (CSE:HUGE) is a cannabis company that holds a license to cultivate cannabis under Access to Cannabis for Medical Purposes Regulations (ACMPR) through its subsidiary FV Pharma Inc. Headquartered at the former Kraft plant in Cobourg, Ontario, the Company originally received its cultivation license on October 13, 2017. FSD Pharma Inc.’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. The Company aims to target all aspects of the cannabis industry – cultivation, processing, manufacturing, extracts and research and development. Continue Reading

FSD Pharma Enters Into Saskatchewan Wholesale Supply MOU of up to 5,000 Kilograms With High Tide Ventures

TORONTOJuly 19, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma”) (CSE:HUGE) (OTC:FSDDF) today announced that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”) has entered into a non-binding memorandum of understanding (“MOU”) with High Tide Ventures Inc. (“High Tide”) dated July 18, 2018 to supply the Saskatchewanmarket on a wholesale basis with up to 5,000 kilograms of cannabis products over the next year when available. FSD Pharma is working together with Auxly (formerly Cannabis Wheaton Income Corp.) (TSX.V:XLY) to achieve its mission to develop the largest hydroponic indoor cannabis cultivation facility in Cobourg, Ontario, Canada.

Continue Reading